A Randomized Phase II, placebo-controlled , multicenter study evaluating efficacy and safety of regorafenib in patients with metastatic bone sarcomas
REGOBONE

Cohort: CIC-rearranged sarcoma

Last cohort still open in Dec 2021

Nom du Centre porteur : UNICANCER
Nom et mail du médecin responsable : Florence Duffaud
florence.duffaud@ap-hm.fr

Centres participants

- 20 centres français

Molécules, schéma de traitement

- **Randomization 2:1 to receive either REGORAFENIB or PLACEBO, until disease progression**
-
- REGORAFENIB : 120 mg /d, 3 weeks on/1 week off OR
- PLACEBO 120 mg/d, 3 weeks on/1 week off
- REG or PLA dosed until unacceptable toxicity or progression

Pts initially randomized to PL could **cross-over to open-label REG after PD confirmation closed**

Indication : metastatic/locally advanced disease, in 2d, 3d or 4th line of treatment

Main inclusion criteria

- Osteosarcoma,Ewing sarcoma of bone, Chondrosarcoma, Chordoma , **CIC-DUX4 sarcoma (either of bone or soft tissue)** *
- Progressive disease at study entry
- **(within prior 3 mo. period** for OsteoS and Ewing , **CIC-DUX4** and within 6 mo. for ChondroS and Chordoma)
- Metastatic disease/local. advanced disease not amenable to surgery or radiation with curative intent
- Measurable disease (RECIST 1.1)
- Prior treatment: at least 1, but no more than 2 prior (combination) chemo regimen for metastatic disease (neo-adjuvant /maintenance therapy are not counted towards this requirement.) for OS, ES, CS and For Chordomas; non pretreated or treated with 1 or 2 prior (combination) chemo OR with 1 or 2 prior targeted therapy (ies), but NO MORE than 2 prior lines of treatment (whatever the indication)
- **For CIC-DUX4 sarcoma at least 1 but no more than 3 prior (combination) chemo regimen**
- Age ≥ 10 years, ECOG PS < 2 (Karnofsky ≥ 60%)
- Dated+ signed the informed consent form

Endpoints and statistics

Primary endpoint: Non-progression rate at 8 weeks

Secondary end points: PFS (per modified RECIST 1.1), OS, Toxicity per NCI-CTC AE v4

Statistical Design per A'Hern's single-stage design for phase II trials (A'Hern et al 2001)

- **H0 25%, H1 55%, one-sided α: 5%; β = 80%**
- **18 patients planned in REGO arm**
- 2:1 Randomization ➔ 27 patients total randomized population
- **≥ 8 progression-free pts at 8 weeks for 'success'**
- **No formal statistical comparison between REGO and PLACEBO**

Etat d'avancement

Etat du recrutement

- Nombre de patients inclus : 4 (3 non évaluables selon l'objectif principal)
- Nombre de patients restant à inclure : 17 patients
- Fermeture prévue le: janvier 2024

Problème/ Amendement à venir

- **Discussion de plusieurs pistes :**

- **Elargir dès la première ligne en rechute**
- **Garder seulement le bras = regorafenib**
- **Augmenter le nombre de centres (Espagne ?)**